Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk

Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo, has received Priority Review from the US FDA for use as a post-neoadjuvant treatment in adult patients with early breast cancer—specifically HER2-positive cases with residual invasive disease after neoadjuvant HER2-targeted therapy. Based on the DESTINY-Breast05 Phase III trial, it showed a 53% reduction in invasive disease recurrence or death risk versus trastuzumab emtansine (T-DM1), with a target action date in Q3 2026. Approval could make it a new standard, tackling unmet needs for patients where half face residual disease and high recurrence.

DESTINY-Breast05 Delivers 53% IDFS Risk Cut vs T-DM1

The DESTINY-Breast05 Phase III trial confirmed Enhertu’s edge, with a 53% drop in invasive disease-free survival (IDFS) events (HR 0.47; 95% CI 0.34-0.66; p<0.0001) over T-DM1, achieving a three-year IDFS rate of 92.4% versus 83.7%. Benefits spanned secondary endpoints: 53% DFS reduction (HR 0.47), 51% lower distant recurrence risk (HR 0.49), and 36% reduced brain metastases risk (HR 0.64). Consistent across subgroups, these results—shared at ESMO 2025 and in the New England Journal of Medicine—could prevent metastatic shift, where survival falls from ~90% to ~30% at five years, impacting ~16,000 US patients yearly in early breast cancer settings.

Trial Design Matches High-Risk HER2 Epidemiology

DESTINY-Breast05 (NCT04622319) randomized 1,635 patients globally with HER2-positive early breast cancer showing residual disease post-neoadjuvant therapy and high recurrence risk (inoperable or node-positive). Participants got Enhertu 5.4 mg/kg or T-DM1, with primary endpoint investigator-assessed IDFS and secondaries like DFS, OS, distant recurrence-free interval, brain metastasis-free interval, and safety. HER2-positive cases (1 in 5 breast cancers) drive aggressive disease; half of neoadjuvant patients have residual disease despite standard care. US stats: >320,000 diagnoses, >42,000 deaths yearly. Enhertu’s safety aligned with prior data, no new signals.

Ad

Priority Status Drives HEOR and Access Shifts

Priority Review, plus Breakthrough Therapy tag and Project Orbis for EU/Japan alignment, fast-tracks Enhertu in early breast cancer. It could offset costs via fewer metastases and better survival for 16,000 annual US patients. Enhertu’s metastatic approvals in 90+ countries will bolster payer talks, fueling discussions on recurrence prevention and resource use for sustainable access in high-risk oncology.